Alzheimer's & Cognition
Cases That Test Your Skills
From sweet to belligerent in the blink of an eye
Ms. P, age 87, presents with mental status changes, agitation, and combativeness. She has a complex medical history and lengthy medication list....
From the Journals
Coding variants in apolipoprotein B may be associated with early-onset Alzheimer’s disease
The finding may help fill out the genetic risk picture for early-onset Alzheimer’s disease.
Conference Coverage
Patients with intellectual disability require nuanced care
SAN FRANCISCO – Dr. Nita V. Bhatt talks with Dr. Julie P. Gentile about best practices for providing psychiatric interventions for patients with...
Commentary
Report on newly recognized cause of dementia should be read widely
The LATE consensus working group reportcalls for systematic study of the causes of dementia.
From the Journals
Experts propose new definition and recommendations for Alzheimer’s-like disorder
Limbic-predominant age-related TDP-43 encephalopathy (LATE) has been coined as a new term to raise awareness and spur research into this recently...
From the Journals
AD biomarker not tied to increased interest in physician-assisted death
When asked whether they had considered PAD, nearly two-thirds of interviewees with the Alzheimer’s disease biomarker stated that they neither had...
From the Journals
Plasma levels of neurofilament light track neurodegeneration in MCI and Alzheimer’s disease
The protein also may be useful to monitor effects in trials of disease-modifying drugs.
News
BACE-1 inhibition worsens cognition in patients with prodromal Alzheimer’s disease
Inhibiting the APP-cleaving enzyme decreased the toxic amyloid species, but it also worsened cognition and caused a variety of concerning adverse...
News
Amyloid brain imaging changed clinical management in 60% of MCI and dementia patients
Results from IDEAS, a prospective imaging study, refined Alzheimer’s disease diagnoses in both amyloid-positive and amyloid-negative cases. Now it...
Latest News
Biogen, Eisai discontinue aducanumab Alzheimer’s trials
All trials – the phase 3 ENGAGE and EMERGE trials, phase 2 EVOLVE safety study, and the long-term extension of the phase 1b PRIME study – have...
MDedge Psychcast
Alzheimer’s update: George Grossberg
Dr. Grossberg lectures on what’s new in Alzheimer’s disease.